Compare YMT & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | CLDI |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.4M |
| IPO Year | 2023 | 2021 |
| Metric | YMT | CLDI |
|---|---|---|
| Price | $0.22 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 849.5K | ★ 1.5M |
| Earning Date | 06-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $45,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.09 |
| 52 Week High | $2.85 | $5.12 |
| Indicator | YMT | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 76.29 |
| Support Level | $0.14 | $1.17 |
| Resistance Level | $0.35 | $1.62 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 5.40 | 81.49 |
Yimutian Inc operates an agricultural B2B platform in China. It provides a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching and matching to transaction facilitation and settlement, through its Yimutian App and Douniu App. Additionally, leveraging its industry experience and market insights, the company has ventured into the realm of smart farming and agricultural sourcing and trading, further broadening its commercialization channels and animating its other business lines. The company operates as a single operating and reportable segment, as it offers a unified set of products and services mainly related to the provision of digital agricultural transaction services.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.